Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2022 07:00 ET | Source: Rezolute, Inc.

Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism

The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability Results to be presented in an oral presentation at a medical congress in 2Q 2022 REDWOOD...
February 22, 2022 07:00 ET | Source: Rezolute, Inc.

Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME

REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases...
February 09, 2022 16:05 ET | Source: Rezolute, Inc.

Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress

REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases...
November 12, 2021 16:05 ET | Source: Rezolute, Inc.

Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress

REDWOOD CITY, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases...
October 13, 2021 08:10 ET | Source: Rezolute, Inc.

Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering

REDWOOD CITY, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies...
October 12, 2021 16:05 ET | Source: Rezolute, Inc.

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering

REDWOOD CITY, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies...
September 22, 2021 16:05 ET | Source: Rezolute, Inc.

Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021

Continuous glucose monitoring reveals undertreated hypoglycemia in patients with congenital hyperinsulinism RZ358, a monoclonal antibody in Phase 2b development, has normalized blood glucose levels...
September 15, 2021 16:56 ET | Source: Rezolute, Inc.

Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress

REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases...
September 09, 2021 16:05 ET | Source: Rezolute, Inc.

Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism

Tracking to Announce Top line data in Q1 2022 REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing...
September 07, 2021 16:05 ET | Source: Rezolute, Inc.

Rezolute to Participate in Upcoming Virtual Healthcare Conferences

REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related...